Equities Analysts Offer Predictions for Harrow Q1 Earnings

Harrow, Inc. (NASDAQ:HROW) – Research analysts at B. Riley cut their Q1 2025 earnings per share (EPS) estimates for Harrow in a research note issued on Monday, March 31st. B. Riley analyst M. Mamtani now expects that the company will post earnings of ($0.01) per share for the quarter, down from their previous forecast of $0.15. B. Riley has a “Buy” rating and a $65.00 price objective on the stock. The consensus estimate for Harrow’s current full-year earnings is ($0.53) per share. B. Riley also issued estimates for Harrow’s FY2025 earnings at $0.78 EPS, FY2026 earnings at $2.67 EPS and FY2027 earnings at $4.79 EPS.

Separately, HC Wainwright reissued a “buy” rating and set a $57.00 price target on shares of Harrow in a report on Monday.

Harrow Trading Up 4.3 %

NASDAQ HROW opened at $26.05 on Thursday. The firm’s fifty day moving average is $28.36 and its two-hundred day moving average is $37.63. Harrow has a one year low of $9.86 and a one year high of $59.23. The company has a debt-to-equity ratio of 3.23, a quick ratio of 1.44 and a current ratio of 1.55. The firm has a market cap of $927.77 million, a PE ratio of -27.71 and a beta of 0.69.

Harrow (NASDAQ:HROW) last announced its earnings results on Thursday, March 27th. The company reported $0.25 EPS for the quarter, beating analysts’ consensus estimates of $0.11 by $0.14. The business had revenue of $66.83 million for the quarter, compared to analysts’ expectations of $66.01 million. Harrow had a negative net margin of 19.75% and a negative return on equity of 45.57%.

Hedge Funds Weigh In On Harrow

Large investors have recently bought and sold shares of the company. GF Fund Management CO. LTD. acquired a new position in shares of Harrow during the fourth quarter worth about $25,000. Tower Research Capital LLC TRC boosted its holdings in Harrow by 769.5% in the 4th quarter. Tower Research Capital LLC TRC now owns 1,652 shares of the company’s stock valued at $55,000 after purchasing an additional 1,462 shares in the last quarter. Aquatic Capital Management LLC acquired a new position in Harrow during the 4th quarter worth approximately $78,000. AlphaQuest LLC raised its stake in shares of Harrow by 452.8% during the 4th quarter. AlphaQuest LLC now owns 3,527 shares of the company’s stock worth $118,000 after buying an additional 2,889 shares in the last quarter. Finally, Federated Hermes Inc. acquired a new stake in shares of Harrow in the 4th quarter valued at approximately $214,000. Hedge funds and other institutional investors own 72.76% of the company’s stock.

Harrow Company Profile

Harrow, Inc operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company was formerly known as Imprimis Pharmaceuticals, Inc and changed its name to Harrow Health, Inc in December 2018. Harrow Health, Inc was incorporated in 2006 and is headquartered in Nashville, Tennessee.